Gain Therapeutics Stock (NASDAQ:GANX)

Forecast Ownership Financials Chart

Previous Close

$1.97

52W Range

$1.41 - $4.34

50D Avg

$2.16

200D Avg

$2.17

Market Cap

$82.37M

Avg Vol (3M)

$686.85K

Beta

0.11

Div Yield

GANX Company Profile

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 19, 2021

Website

GANX Performance

GANX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	$55.18K
Operating Income	$-18.71M	$-20.35M	$-22.25M
Net Income	$-20.16M	$-20.41M	$-22.27M
EBITDA	$-18.71M	$-20.27M	$-22.17M
Basic EPS	$-0.61	$-0.89	$-1.71
Diluted EPS	$-0.61	$-0.89	$-1.71

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
OSTX	OS Therapies Incorporated
LITS	Lite Strategy, Inc.
TCRX	TScan Therapeutics, Inc.
CRVO	CervoMed Inc.
NRXP	NRx Pharmaceuticals, Inc.
ADAG	Adagene Inc.
FBIO	Fortress Biotech, Inc.
NTRB	Nutriband Inc.
XBIT	XBiotech Inc.
ACET	Adicet Bio, Inc.